| abstract |
The invention belongs to the technical field of medicine, and relates to the application of a biphenylcyclooctene type lignan compound of the general formula (I) and a microbial transformation product thereof in medicines for treating and preventing diseases related to the activation of microglial cells. The structure of the compound can be in three conformations: biphenyl S configuration TBC eight-membered ring conformation; biphenyl R configuration TBC eight-membered ring conformation; biphenyl S configuration TB eight-membered ring conformation. R 1 , R 2 , R 3 , R 4 , R 5 , R 6 are hydrogen, hydroxy, methoxy, angelate, acetate, benzoate, ciserythate or o-methylenedioxy base. R 7 , R 8 are hydrogen, hydroxyl, methoxy, keto, angelate, acetate, benzoate, ciserythrate, and can form a three-membered oxygen bridge with an oxygen atom, or with R 3 , The 4 -position of R forms a macrocyclic lactone, and if it is a chiral center, its configuration can be S-type or R-type. R 9 , R 10 , R 11 , and R 12 are hydrogen, methyl, hydroxyl, ketone or double bond, and if they are chiral centers, their configuration can be S or R. (I) |